Lytix Biopharma Past Earnings Performance
Past criteria checks 0/6
Lytix Biopharma's earnings have been declining at an average annual rate of -22.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.4% per year.
Key information
-22.5%
Earnings growth rate
-11.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 18.4% |
| Return on equity | -219.7% |
| Net Margin | -752.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Lytix Biopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 11 | -81 | 20 | 60 |
| 30 Jun 24 | 14 | -76 | 22 | 57 |
| 31 Mar 24 | 15 | -86 | 25 | 68 |
| 31 Dec 23 | 4 | -88 | 24 | 63 |
| 30 Sep 23 | 14 | -99 | 25 | 62 |
| 30 Jun 23 | 11 | -91 | 23 | 62 |
| 31 Mar 23 | 11 | -61 | 22 | 50 |
| 31 Dec 22 | 11 | -56 | 20 | 46 |
| 30 Sep 22 | 8 | -43 | 25 | 42 |
| 30 Jun 22 | 3 | -51 | 25 | 42 |
| 31 Mar 22 | 4 | -63 | 23 | 35 |
| 31 Dec 21 | 19 | -48 | 31 | 24 |
| 30 Sep 21 | 4 | -44 | 30 | 30 |
| 30 Jun 21 | 7 | -40 | 35 | 22 |
| 31 Mar 21 | 6 | -35 | 35 | 19 |
| 31 Dec 20 | 4 | -42 | 25 | 16 |
| 31 Dec 19 | 6 | -33 | 23 | 14 |
| 31 Dec 18 | 12 | -62 | 22 | 40 |
| 31 Dec 17 | 14 | -69 | 24 | 47 |
Quality Earnings: 6BG is currently unprofitable.
Growing Profit Margin: 6BG is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6BG is unprofitable, and losses have increased over the past 5 years at a rate of 22.5% per year.
Accelerating Growth: Unable to compare 6BG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6BG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 6BG has a negative Return on Equity (-219.68%), as it is currently unprofitable.